ERBB2 and neoplasm: Currently, HER2 status is determined ex vivo on biopsy or pathological specimens using several different methods: immunohistochemical assessment (IHC), enzyme-linked immunosorbent assay (ELISA) of serum or tumor cytosol, and Western blot test for overexpression of HER2 protein.